Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center

Cutaneous melanoma is a highly aggressive skin cancer. It is estimated that 5% to 10% of the underlying mutations are hereditary and responsible for familial (or hereditary) melanoma. These patients are prone to the early development and higher risk of multiple melanomas. In recent years, an increasing number of genes have been identified thanks to genetic testing, allowing the subsequent surveillance of individuals at risk, yet it is still difficult to predict the presence of these mutations on a clinical basis. In this scenario, specific phenotypic and dermoscopic features could help clinicians in their identification. The aim of this work has been to correlate mutations to prevalent dermoscopic patterns, paving the way for reference models useful in clinical practice. In our cohort, out of 115 patients referred to genetic counseling for melanoma, 25 tested positive (21.7%) for critical mutations: CDKN2A (n = 12), MITF (n = 3), BAP1 (n = 1), MC1R (n = 3), PTEN (n = 1), TYR (n = 2), OCA2 (n = 1), and SLC45A2 (n = 2). The phenotype profiles obtained through the digital acquisition, analysis, and description of both benign and malignant pigmented lesions showed a predominance of the type II skin phenotype, with an elevated mean total nevus number (182 moles, range 75–390). As for dermoscopic features, specific mutation-related patterns were described in terms of pigmentation, areas of regression, and vascular structures. Although further studies with larger cohorts are needed, our work represents the beginning of a new approach to the study and diagnosis of familial melanoma, underlining the importance of clinical and dermoscopic patterns, which may constitute a reference model for each gene, enabling comparison.

[1]  B. Pasini,et al.  BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome. , 2022, Melanoma research.

[2]  I. Zalaudek,et al.  Extensive “halo naevi” phenomenon and regression of melanin during nivolumab treatment in metastatic melanoma: A predictor of a better outcome? , 2022, Dermatologic therapy.

[3]  N. Serman,et al.  Genetic risk factors in melanoma etiopathogenesis and the role of genetic counseling: A concise review , 2022, Bosnian journal of basic medical sciences.

[4]  M. Aglietta,et al.  Current Controversies and Challenges on BRAF V600K-Mutant Cutaneous Melanoma , 2022, Journal of clinical medicine.

[5]  P. Queirolo,et al.  Clinical Significance of Distant Metastasis-Free Survival (DMFS) in Melanoma: A Narrative Review from Adjuvant Clinical Trials , 2021, Journal of clinical medicine.

[6]  J. Valls,et al.  Differential Immunoexpression of BRAF/V600E, Senescence Markers, PTEN, and T-type Calcium Channels in Acquired Naevi According to their Histopathological and Dermoscopic Classification , 2021, Acta dermato-venereologica.

[7]  L. Alós,et al.  Molecular Markers and Targets in Melanoma , 2021, Cells.

[8]  S. Puig,et al.  Familial Melanoma and Susceptibility Genes: A Review of the Most Common Clinical and Dermoscopic Phenotypic Aspect, Associated Malignancies and Practical Tips for Management , 2021, Journal of clinical medicine.

[9]  A. Geller,et al.  Epidemiology of Melanoma. , 2021, Hematology/oncology clinics of North America.

[10]  H. Soyer,et al.  Germline and somatic albinism variants in amelanotic/hypomelanotic melanoma: Increased carriage of TYR and OCA2 variants , 2020, PloS one.

[11]  J. Welborn,et al.  Germline mutations predisposing to melanoma , 2020, Journal of cutaneous pathology.

[12]  C. Massone,et al.  Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients , 2020, Journal of Translational Medicine.

[13]  P. Ascierto,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  A. Scope,et al.  Dermoscopy of naevi in patients with oculocutaneous albinism , 2019, Clinical and experimental dermatology.

[15]  K. Liopyris,et al.  Dermoscopy: A Review of the Structures That Facilitate Melanoma Detection , 2019, The Journal of the American Osteopathic Association.

[16]  J. Malvehy,et al.  Melanocortin 1 receptor (MC1R) polymorphisms’ influence on size and dermoscopic features of nevi , 2018, Pigment cell & melanoma research.

[17]  J. Malvehy,et al.  Amelanotic melanoma in oculocutaneous albinism: a genetic, dermoscopic and reflectance confocal microscopy study , 2017, The British journal of dermatology.

[18]  Giuseppe Argenziano,et al.  A meta‐analysis of nevus‐associated melanoma: Prevalence and practical implications , 2017, Journal of the American Academy of Dermatology.

[19]  C. Longo,et al.  592 Clinical, dermoscopic and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation , 2017 .

[20]  C. Shea,et al.  Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature , 2017, JAMA dermatology.

[21]  M A Weinstock,et al.  The global burden of melanoma: results from the Global Burden of Disease Study 2015 , 2017, The British journal of dermatology.

[22]  K. Peris,et al.  Characterization of melanoma susceptibility genes in high-risk patients from Central Italy , 2017, Melanoma research.

[23]  S. Kawana,et al.  Melanotic Malignant Melanoma in Oculocutaneous Albinism Type 4. , 2017, Acta dermato-venereologica.

[24]  N. Gruis,et al.  The absence of multiple atypical nevi in germline CDKN2A mutations: Comment on "Hereditary melanoma: Update on syndromes and management: Genetics of familial atypical multiple mole melanoma syndrome". , 2016, Journal of the American Academy of Dermatology.

[25]  P. Galan,et al.  The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. , 2016, The Journal of clinical endocrinology and metabolism.

[26]  Nicola D. Roberts,et al.  Germline MC1R status influences somatic mutation burden in melanoma , 2016, Nature Communications.

[27]  M. Askarian-Amiri,et al.  Signaling Pathways in Melanogenesis , 2016, International journal of molecular sciences.

[28]  D. Glass,et al.  Genetic epidemiology of melanoma , 2016, European Journal of Dermatology.

[29]  S. Puig,et al.  Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. , 2016, The Journal of investigative dermatology.

[30]  H. Tsao,et al.  Hereditary melanoma: Update on syndromes and management: Emerging melanoma cancer complexes and genetic counseling. , 2016, Journal of the American Academy of Dermatology.

[31]  P. Ascierto,et al.  Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. , 2016, Journal of the American Academy of Dermatology.

[32]  J. Little,et al.  MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project , 2015, British Journal of Cancer.

[33]  A. Andrén-sandberg,et al.  Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. , 2015, JAMA surgery.

[34]  J. Malvehy,et al.  Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom , 2014, Hereditary cancer in clinical practice.

[35]  Carlo Riccardo Rossi,et al.  Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. , 2014, In vivo.

[36]  Sikandar G. Khan,et al.  High frequency of PTEN mutations in nevi and melanomas from xeroderma pigmentosum patients , 2014, Pigment cell & melanoma research.

[37]  S. Rosso,et al.  MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors , 2014, Pigment cell & melanoma research.

[38]  O. Abbas,et al.  Cutaneous Malignant Melanoma: Update on Diagnostic and Prognostic Biomarkers , 2014, The American Journal of dermatopathology.

[39]  J. Malvehy,et al.  Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population , 2013, The British journal of dermatology.

[40]  K. Hemminki,et al.  Variants at the 9p21 locus and melanoma risk , 2013, BMC Cancer.

[41]  Giovanni Pellacani,et al.  CDKN2A and MC1R variants influence dermoscopic and confocal features of benign melanocytic lesions in multiple melanoma patients , 2013, Experimental dermatology.

[42]  N. Hayward,et al.  Prevalence of germline BAP1 mutation in a population‐based sample of uveal melanoma cases , 2013, Pigment cell & melanoma research.

[43]  P. Queirolo,et al.  Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history , 2013, Pigment cell & melanoma research.

[44]  Thomas Krausz,et al.  BAP1 and cancer , 2013, Nature Reviews Cancer.

[45]  R. Wolterbeek,et al.  Melanocortin 1 receptor (MC1R) variants in high melanoma risk patients are associated with specific dermoscopic ABCD features. , 2012, Acta dermato-venereologica.

[46]  L. Larue,et al.  PTEN and melanomagenesis. , 2012, Future oncology.

[47]  Peter Boyle,et al.  Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[48]  L. Chin,et al.  Melanoma: from mutations to medicine. , 2012, Genes & development.

[49]  Ivana K. Kim,et al.  Germline BAP1 Inactivation Is Preferentially Associated with Metastatic Ocular Melanoma and Cutaneous-Ocular Melanoma Families , 2012, PloS one.

[50]  K. Brown,et al.  A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma , 2011, Nature.

[51]  S. Puig,et al.  A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma , 2011, Nature.

[52]  H. Putter,et al.  Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. , 2011, Journal of the American Academy of Dermatology.

[53]  J. Malvehy,et al.  Early stages of melanoma on the limbs of high-risk patients: clinical, dermoscopic, reflectance confocal microscopy and histopathological characterization for improved recognition. , 2011, Acta dermato-venereologica.

[54]  J. Barrett,et al.  Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK , 2011, Journal of Medical Genetics.

[55]  Gail M Williams,et al.  Reduced melanoma after regular sunscreen use: randomized trial follow-up. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  S. Puig,et al.  Association of MC1R Variants and Host Phenotypes With Melanoma Risk in CDKN2A Mutation Carriers: A GenoMEL Study , 2010, Journal of the National Cancer Institute.

[57]  K. Nielsen,et al.  Swedish CDKN2A mutation carriers do not present the atypical mole syndrome phenotype , 2010, Melanoma research.

[58]  A. Marghoob,et al.  Defining the patient at high risk for melanoma , 2010, International journal of dermatology.

[59]  A. Halpern,et al.  Selection criteria for genetic assessment of patients with familial melanoma. , 2009, Journal of the American Academy of Dermatology.

[60]  J. Lundeberg,et al.  MC1R variation and melanoma risk in the Swedish population in relation to clinical and pathological parameters , 2009, Pigment cell & melanoma research.

[61]  J. Malvehy,et al.  Dermoscopic features of melanomas associated with MC1R variants in Spanish CDKN2A mutation carriers , 2009, The British journal of dermatology.

[62]  F. Sera,et al.  MC1R variants, melanoma and red hair color phenotype: A meta‐analysis , 2008, International journal of cancer.

[63]  N. Hayward,et al.  Cutaneous melanoma susceptibility and progression genes. , 2005, Cancer letters.

[64]  L. Cannon-Albright,et al.  Population-based analysis of prognostic factors and survival in familial melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  J. Malvehy,et al.  Role of the CDKN2A locus in patients with multiple primary melanomas. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  L. Cannon-Albright,et al.  Longitudinal assessment of the nevus phenotype in a melanoma kindred. , 2004, The Journal of investigative dermatology.

[67]  C. Lebbé,et al.  Melanocortin 1 receptor (MC1R) gene variants may increase the risk of melanoma in France independently of clinical risk factors and UV exposure , 2004, Journal of Medical Genetics.

[68]  Hensin Tsao,et al.  A population‐based analysis of risk factors for a second primary cutaneous melanoma among melanoma survivors , 2003, Cancer.

[69]  Florence Demenais,et al.  Geographical variation in the penetrance of CDKN2A mutations for melanoma. , 2002, Journal of the National Cancer Institute.

[70]  W. Clark,et al.  A natural history of melanomas and dysplastic nevi , 2002, Cancer.

[71]  P. Aegerter,et al.  Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. , 2001, Archives of dermatology.

[72]  R. Willemze,et al.  Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. , 2001, The Journal of investigative dermatology.

[73]  J. Struewing,et al.  Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. , 2000, Journal of the National Cancer Institute.

[74]  D. Bishop,et al.  Mutation screening of the CDKN2A promoter in melanoma families , 2000, Genes, chromosomes & cancer.

[75]  W. Cavenee,et al.  In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[76]  J. Mark Elwood,et al.  Melanoma and sun exposure: An overview of published studies , 1997, International journal of cancer.

[77]  N. Martin,et al.  Characterization of melanocyte stimulating hormone receptor variant alleles in twins with red hair. , 1997, Human molecular genetics.

[78]  M. Qadir,et al.  Malignant Melanoma: Skin Cancer-Diagnosis, Prevention, and Treatment. , 2020, Critical reviews in eukaryotic gene expression.

[79]  D. Duffy,et al.  Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. , 2014, The Journal of investigative dermatology.

[80]  Jeffrey E. Lee,et al.  Natural and orthogonal model for estimating gene–gene interactions applied to cutaneous melanoma , 2013, Human Genetics.

[81]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. , 2005, European journal of cancer.

[82]  P. Boyle,et al.  Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. , 2005, European journal of cancer.

[83]  D. Duffy,et al.  Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? , 2000, American journal of human genetics.